Publications by authors named "Mathias Dewatripont"

Claim this Profile
P
Prescription opioids and economic hardship in France.
Ilaria Natali, Mathias Dewatripont, Victor Ginsburgh, Michel Goldman, Patrick Legros

Eur J Health Econ· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the impact of COVID-19 passes and mandates on disease transmission, vaccination intention, and uptake: a scoping review.
Yessika Adelwin Natalia, Margaux Delporte, Dries De Witte, Philippe Beutels, Mathias Dewatripont

BMC Public Health· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel approach to boost drug development in paediatric oncology.
Sam Daems, Hilde Stevens, Mathias Dewatripont, Hans-Georg Eichler, Michel Goldman

Nat Rev Drug Discov· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Therapeutic innovation for the common good].
Michel Goldman, Mathias Dewatripont, Alain Fischer

Med Sci (Paris)· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Confirmed COVID-19 Cases per Economic Activity during Autumn Wave in Belgium.
Johan Verbeeck, Godelieve Vandersmissen, Jannes Peeters, Sofieke Klamer, Sharon Hancart, Mathias Dewatripont

Int J Environ Res Public Health· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preparing for a responsible lockdown exit strategy.
Marius Gilbert, Mathias Dewatripont, Eric Muraille, Jean-Philippe Platteau, Michel Goldman

Nat Med· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[What is the fair price of innovative therapy?].
Alain Fischer, Mathias Dewatripont, Michel Goldman

Med Sci (Paris)· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefit Corporation: a path to affordable gene therapies?
Alain Fischer, Mathias Dewatripont, Michel Goldman

Nat Med· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Free Drug Samples and the Opioid Crisis.
Mathias Dewatripont, Michel Goldman

N Engl J Med· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis